Drugs / SCH-58500
SCH-58500
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00004080 | Dec 1999 → ? | central nervous system neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00002960 | Jun 1999 → Jul 2000 | fallopian tube cancer, metastatic malignant neoplasm, ovarian cancer, peritoneum cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00003880 | Feb 1999 → Aug 2001 | ovarian cancer, primary peritoneal carcinoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCH 58500 | “A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.” PMID 12082455 ↗ Jul 2002 |
| Known as | rAd/p53 | “A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.” PMID 12082455 ↗ Jul 2002 |
| Known as | recombinant adenovirus-p53 | “recombinant adenovirus-p53 SCH-58500” NCT00003880 ↗1“recombinant adenovirus-p53 SCH-58500” NCT00004080 ↗ |
| Action | Restore | “p53 gene replacement” PMID 12082456 ↗ Jul 2002 |
| Modality | Gene therapy (AAV / viral vector) | “gene therapy using SCH-58500” NCT00003880 ↗ |
| Route | Other | “delivered into the peritoneal cavity (i.p.)” PMID 12082455 ↗ Jul 2002 |